APRIL 21-23, 2020

BOSTON, MA USA

Consumer track focuses on challenges and progress insights for companies creating microbiome-based consumer products and services

MINNEAPOLIS, March 6, 2018– Arrowhead Publishers released a parallel consumer track agenda for the 4th Annual Translational Microbiome Conference, April 18-20 in Boston. The conference is designed to bring together scientists at the forefront of microbiome research with pioneering business leaders at companies innovating microbiome-based medical solutions. The consumer track focuses on issues and learnings around direct-to-consumer product and service development, with an eye toward helping companies successfully (and efficiently) navigate from research and product innovation through regulation, commercialization and marketing.

“Microbiome research is delivering medical advancements across oncology, dermatology, inflammatory disorders, mental health and many related fields,” said John Waslif, Managing Director of Arrowhead Publishers. “The consumer track at our 4th Annual Translational Microbiome Conference provides a forum for companies to share best practices and process solutions. People want to take control of their health with access to the same science that’s making headlines in leading hospitals and medical labs, and we want to help speed the path to commercialization.”
As recent discoveries illustrate the many essential roles the human microbiome plays within the human ecosystem, scientists are discovering specific variables within the microbiome can profoundly impact a variety of conditions and diseases. To support exploration of translational consumer applications, consumer track presentations and discussion topics are broadly applicable, spanning multiple disease states and addressing issues common to companies in this space.


Consumer track sessions include:
Probiotic Hygiene and Care Response
Robin Temmerman, Ph.D., Chief Executive Officer, Chrisal, N.V.
Resistance of microbes to antibiotics and disinfectants is growing quickly, and allergies to chemical ingredients in cleaning and personal care products are on the rise. Rapid evolution in microbiological research has led to promising new probiotic hygiene technologies in the form of cleaning and personal care applications. For the past 15 years, Chrisal has invested to develop product solutions to widespread hygiene problems like biofilm, smell and infections. Dr. Temmerman will discuss the technology, mechanisms and benefits of probiotic hygiene and care.

Probiotic Home: The Future of Clean
John Howell, Industry Technology Specialist HHC, Novozymes
Consumers are increasingly aware of the microbiota surrounding them, and its integral role in their healthy lifestyle. They may not yet think of microbiota as a solution to what they spill on the floor. Yet, microorganisms, or probiotics, are nature’s oldest and most reliable cleaning crew. They work overtime to break down organics, for a deeper and longer-lasting “probiotic clean” than conventional chemicals. While the technology has long been used industrially, this concept has just recently started to resonate with consumers for application in their home environment. Mr. Howell will share several industrial and domestic cleaning scenarios in which microorganism-containing products are currently used, and he’ll predict future consumer cleaning habits and products that will selectively reinforce the microbiome of the home.

Panel Session: The Future of Probiotic Hygiene
Moderated by Joe Rubino, R&D Director for Reckitt Benckiser, panelists will include Matt Franken, Chief Executive Officer of Aunt Fannies; Robin Temmerman, Ph.D., Chief Executive Officer of Chrisal N.V. and other industry experts.

Early Life Microbiome: Connections between Nutritional Composition, Gastrointestinal Tract and the Brain
Maciej Chichlowski, Ph.D., PMP, Principal Scientist, Mead Johnson Nutrition (RB)
Optimal development of the microbiome is an emerging health benefit that’s likely to grow in consumer awareness and demand over time. Intestinal microbiota plays a role in metabolic, nutritional, physiological and immunological processes in the human body, and nutrition can affect gut microbiota colonization. Our research demonstrates that functional properties of early nutrition could benefit the microbiome and health. For instance, our studies have shown that early life diet with milk fat globule membrane and prebiotics promote immune, gut, and brain development and function.

Using Live Bacteria for Topical Skin Application: Regulatory Issues
Ingmar Claes, Ph.D., Chief Scientific Officer, Yun Probiotherapy
A growing body of data supports the importance of the skin microbiome in its role as a protective barrier against external influence. Products with live beneficial bacteria, or live biotherapeutic products (LBP’s), present the potential to improve symptoms of a multitude of skin disorders. Yet, safety of probiotic strains is of critical importance during the in vitro screening phase. By building up the safety documentation and quality controls in the production of products, Yun Probiotherapy was able to overcome EU regulatory issues and begin marketing their LBP line to consumers.

“Research in the microbiome presents tremendous potential to provide more effective treatments, cures, therapies and supplements,” said Waslif. “As investment opportunities are growing in this area, many companies are rapidly pursuing potential translational solutions. Therefore, sharing key learnings in this space can lend greater efficiency to the development and availability of new pharmaceutical offerings.”

View the full agenda for the 4th Annual Translational Microbiome Conference at www.microbiomeconference.com.
Sponsors and Exhibitors can showcase products and branding in an environment designed to facilitate professional networking. Learn more via www.microbiomeconference.com/sponsor-exhibit.

If you would like more information about this announcement or the 4th Annual Translational Microbiome Conference, please contact John Waslif, Managing Director at Arrowhead Publishers via email at This email address is being protected from spambots. You need JavaScript enabled to view it..

Continuing Medical Education Credits Now Available for this Event

Joint-Providership Accreditation and Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Office of Continuing Medical Education of the University of Virginia School of Medicine and Arrowhead Publishers. The Office of Continuing Medical Education of the University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians

The University of Virginia School of Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity. (The number of credits offered for this event is subject to change dependent upon future additions/revisions to the agenda.)

The University of Virginia School of Medicine, as accredited provider, awards 8 hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)TM ) to a participant who successfully completes this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.

Shahram Lavasani, Ph.D.

Founder, Chief Executive Officer and Chief Scientific Officer
Immune Biotech

Profile coming soon.

Scott Jackson, Ph.D.

Group Leader, Complex Microbial Systems
NIST (National Institute of Standards & Technology

Profile coming soon.

Rachel Clemens, Ph.D.

Commerical Innovation Manager, Life Science Lead
ISS US National Lab, Center for Advancement in Science in Space

Profile coming soon.

Lynne Elmore, Ph.D.

Director, Translational Cancer Research Program
American Cancer Society

Lynne Elmore, PhD, is the director of the Translational Cancer Research program in the Extramural Grants department of the American Cancer Society (ACS). She manages a research portfolio focused on cell biology, infectious disease, the microbiome, molecular genetics, and cancer drug discovery.

Garth Ehrlich, Ph.D.

Professor of Microbiology & Immunology, Professor of Otolayngology - Head & Neck Surgery
Drexel University College of Medicine

Dr Ehrlich is Professor of Microbiology and Immunology, and Otolaryngology-Head and Neck Surgery at Drexel University College of Medicine (DUCOM) in Philadelphia, PA, USA. Dr. Ehrlich is also the founder and director of three Research Centers of Excellence in the Institute for Molecular Medicine and Infectious Disease: the Center for Genomic Sciences (CGS); the Center for Advanced Microbial Processing (CAMP); and the Center for Surgical Infections and Biofilms.

He also directs Drexel University’s Core Genomics Facility and the Meta-Omics Shared Resource for the Sidney Kimmel Cancer Center – an NCI-designated Cancer Center.

Momo Vuyisich, Ph.D.

Chief Scientific Officer
Viome

Momo Vuyisich is a co-founder and Chief Science Officer at Viome, a data-driven personalized nutrition company. Momo provides scientific leadership at Viome and his vision is to revolutionize healthcare from "symptoms management" to a true preventative medicine. He leads product development, clinical test implementation, and comprehensive clinical research portfolio.

Momo is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Before co-founding Viome in 2016, Momo spent 12 years at Los Alamos National Laboratory, where he led the Applied Genomics team, which developed the core technology used by Viome today.

Nancy Caralla

Founding President, Executive Director
C Diff Foundation

Nancy C Caralla is a three-time Clostridioides difficile infection (CDI) survivor. She has accumulated over 25 years of experience in the nursing profession blended with over 30 years in international construction management. Over the past several years, Nancy, in partnership with C Diff Foundation members, has focused on raising C. difficile awareness through education and advocating for Clostridium difficile infection prevention, treatments, clinical trials, AMR, and environmental safety worldwide. The C Diff Foundation is a non-profit organization that takes great pride in its volunteers, chairpersons, and committees.

Rachel Teitelbaum, Ph.D.

Chief Executive Officer
Hervana

Profile coming soon.

Sonia Timerlake, Ph.D.

Vice President of Research
Finch Therapeutics

Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.

Dae-Wook Kang, Ph.D.

Assistant Professor, Department of Civil & Environmental Engineering
University of Toledo

Profile coming soon.

Sameer Sonkusale, Ph.D.

Prof. of Electrical & Computer Engineering, Prof. of Biomedical Engineering (adjunct), Director/Principal Investigator, Nano Lab
Tufts University

Profile coming soon.

Amy Feehan, Ph.D.

Research Scientist
Ochsner Health System

Dr. Feehan is an early stage investigator who received her BS and PhD in Neuroscience from The Brain Institute at Tulane University in New Orleans. She has conducted research in humans and rodents covering topics ranging from drug development of novel endomorphin analogs for pain, to sleep and circadian rhythms research and most recently the gut-brain axis and infectious disease. Her doctoral work led to two patents for a compound that reverses both acute and chronic pain with no observable risk of addiction. She currently works as a research scientist in the Infectious Disease department at Ochsner in New Orleans designing and executing investigator-initiated clinical trials.